EOLS vs. TNGX, PLRX, ZNTL, ALXO, LBPH, ETNB, PRAX, SAGE, OPK, and ARQT
Should you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Tango Therapeutics (TNGX), Pliant Therapeutics (PLRX), Zentalis Pharmaceuticals (ZNTL), ALX Oncology (ALXO), Longboard Pharmaceuticals (LBPH), 89bio (ETNB), Praxis Precision Medicines (PRAX), Sage Therapeutics (SAGE), OPKO Health (OPK), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical preparations" industry.
Evolus (NASDAQ:EOLS) and Tango Therapeutics (NASDAQ:TNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
Evolus currently has a consensus target price of $20.60, indicating a potential upside of 57.01%. Tango Therapeutics has a consensus target price of $17.25, indicating a potential upside of 121.44%. Given Tango Therapeutics' higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Evolus.
Evolus has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Evolus has a net margin of -27.31% compared to Tango Therapeutics' net margin of -299.88%. Evolus' return on equity of 0.00% beat Tango Therapeutics' return on equity.
Evolus has higher revenue and earnings than Tango Therapeutics. Evolus is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
90.7% of Evolus shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 5.4% of Evolus shares are owned by company insiders. Comparatively, 6.2% of Tango Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Evolus received 328 more outperform votes than Tango Therapeutics when rated by MarketBeat users. Likewise, 71.94% of users gave Evolus an outperform vote while only 56.52% of users gave Tango Therapeutics an outperform vote.
In the previous week, Evolus had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 19 mentions for Evolus and 17 mentions for Tango Therapeutics. Evolus' average media sentiment score of 0.51 beat Tango Therapeutics' score of -0.19 indicating that Evolus is being referred to more favorably in the media.
Summary
Evolus beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Evolus News Delivered to You Automatically
Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
